StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BofA Securities on Biogen (BIIB): 'clear positive trend in execution'
March 30, 2026 4:41 PM
BofA Securities analyst Tim Anderson reiterated a Neutral rating and $207.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "Biogen ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
